In a groundbreaking revelation, dupilumab has emerged as a game-changer for patients battling moderate to severe asthma, and it works wonders even in those juggling chronic rhinosinusitis (CRS) or nasal polyposis (NP). Recent data unveiled at the prestigious American Thoracic Society's International Conference 2025 highlights these remarkable findings from the global RAPID registry.

Study Details: A Closer Look at the Research

The prospective observational study tracked 205 participants, aged 12 and older, who embarked on dupilumab treatment tailored to their country's guidelines. Dr. Andreanne Cote from the Institut Universitaire de Cardiologie et de Pneumologie de Québec revealed that the participants were split into two distinct groups: 94 with ongoing CRS and/or NP and 111 without.

Asthma Exacerbations? Not an Issue!

Fast forward to week 52, and results showed that both groups were experiencing similar annualized rates of severe asthma exacerbations—0.146 for those with CRS/NP and 0.129 for those without. This indicates that dupilumab isn't just effective but consistent across varying patient profiles.

Significant Improvement in Symptoms!

For the patients grappling with CRS and/or NP, dupilumab significantly alleviated their symptoms, as reflected in the Sino-Nasal Outcome Test-22 (SNOT-22) scores. After just one month of treatment, scores dropped by a substantial 15.2 points, improving even further to 19.8 points after six months and stabilizing at 17.0 points by month 12.

Asthma Control: The Results Don’t Lie!

The study didn’t just stop at CRS symptoms; it also emphasized profound enhancements in asthma control across both groups. Participants with CRS/NP saw their Asthma Control Questionnaire (ACQ-6) scores decrease by an impressive 0.9 points by month 1 and climbing to a 1.3-point drop by month 12. Astonishingly, those without CRS/NP recorded similar gains.

Why This Matters?

Dr. Cote and her team emphasize that asthma often collides with type 2 inflammatory conditions like CRS and NP, resulting in a double whammy of poor asthma management and a lower quality of life. Dupilumab operates by inhibiting pivotal inflammatory pathways, effectively targeting the core issues influencing both asthma and these related conditions.

What Lies Ahead?

With dupilumab's FDA approval journey spanning back to October 2018 for moderate-to-severe asthma in ages 12 and above, and additional approvals extending its reach to different age groups and conditions, the medication is proving to be an essential tool for clinicians.

These promising findings from the RAPID registry don't just add to the clinical lexicon—they reshape our approach to managing asthma intertwined with type 2 inflammation, offering hope for countless patients worldwide.